Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study observed that finasteride use among men with benign prostatic hyperplasia was associated with a decreased incidence of low-grade prostate cancer but not high-grade tumors.

This study found that early-onset androgenic alopecia is associated with a higher risk of developing prostate cancer, although it was not linked to earlier diagnosis or more aggressive tumors.

This study found that Monascus cursory extraction reduced baldness, prostate hyperplasia, and tumor incidence in animal models of androgen-related diseases, suggesting it may be a promising new therapeutic candidate.

This study found an association between vertex baldness and prostate cancer, especially for high-grade tumors in men aged 60-69, suggesting a possible shared androgen pathway.

The literature review concluded that while 5α-reductase inhibitors hold promise for managing prostate cancer, they raise significant safety concerns regarding their association with high-grade tumors and mortality, highlighting the need for careful consideration in their clinical use.

This retrospective study observed no significant difference in the prevalence of incidental prostate cancer between suprapubic prostatectomy and transurethral prostate resection groups, with most tumors being well differentiated and early-stage.

This study found that ACE2 and TMPRSS2 genes were more highly expressed in tumors of elderly male cancer patients compared to healthy individuals, with notable differences across age and gender.

Finasteride helps hair growth and prostate issues but may cause sexual side effects and increase tumor risk.

This research found that a novel dehydroepiandrosterone derivative (12) significantly reduces cell viability and increases apoptosis in testosterone-stimulated normal and tumor prostate cells, unlike finasteride and dutasteride, which also showed activity under dihydrotestosterone stimulation.

Scientists at the University of Michigan Medical School successfully created a special compound that can be used to improve imaging of prostate cancer.

This article discusses the role of 5-alpha-reductase inhibitors in prostate cancer prevention and highlights a medical quandary, but it reports no new clinical findings.

In this study, ginsenoside 20(S)-protopanaxadiol-aglycone (PPD) was shown to downregulate androgen receptor expression and inhibit tumor growth in prostate cancer cells.

CEC levels may be a useful marker for predicting prostate cancer progression.

In this study, dutasteride more effectively reduced prostate cancer cell viability than finasteride in vitro, but did not significantly alter the angiogenic response.

This review concludes that while many epidemiological studies suggest high alcohol intake is associated with an increased risk of prostate cancer, the evidence may be affected by confounding factors such as diet and lifestyle.

This paper discusses prostate cancer diagnosis and treatment controversies and advocates for individualized approaches, reporting no new findings.

This review explores plant-derived phytochemicals, such as phytosterols, polyphenols, and fatty acids, for their potential use as alternative treatments for prostate cancer, emphasizing their effects on 5-alpha-Reductase enzyme isozymes. It reports no new clinical results.

This study found that the co-activator CBP enhances the agonistic action of hydroxyflutamide on androgen receptors, suggesting a mechanism for therapy resistance in prostate cancer.

This study found that 5‐α‐reductase inhibitors reduce the risk of being diagnosed with prostate cancer in men who undergo regular screening, but increase the risk of sexual and erectile dysfunction.

This article concludes that finasteride is a safe treatment for androgenetic alopecia and does not increase the risk of high-grade prostate cancer, despite past concerns from the Prostate Cancer Prevention Trial.

Results are not reported for this study, which used a directed acyclic graph to analyze the association between chest hair amount and prostate cancer, adjusting for age and ancestry.

This study reports two cases where localized prostate cancer with low PSA levels was incidentally detected through CT scans performed for other medical reasons.

In this case study, a male miniature dachshund with alopecia was diagnosed with estrogen-secreting Sertoli cell tumors and seminoma, with the alopecia resolving post-surgical removal of the tumor.

This review suggests that finasteride at 1 mg/day reduces PSA levels similarly to 5 mg/day, but differences in prostate dihydrotestosterone levels may affect prostate cancer diagnosis and prevention.

This study found that early treatment with estradiol or dihydrotestosterone significantly reduced prostate adenocarcinoma development in Lobund-Wistar rats, while later treatments were ineffective.

Higher BMI is linked to a lower risk of non-aggressive prostate cancer and a higher risk of aggressive prostate cancer.

The document concludes that a new biosensor can efficiently detect prostate cancer cells and that standardized referrals help find significant cancers effectively.

This discussion proposes a model to incorporate patients with hormone-resistant prostate cancer into the existing framework by redefining hormone resistance and exploring new therapeutic approaches.

This review explores the potential impact of hormonal changes during aging on benign prostate hyperplasia-related urinary symptoms and metabolic syndrome, highlighting the hypothesis of a male PCOS-equivalent but reports no new clinical results.

This research discusses the potential antitumor effects of metformin, a common diabetes medication, noting its controversial influence on different malignant tumors and its uncertain mechanisms. Understanding these effects on tumors may aid in the development of new cancer treatments.